RNAi Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: January 20, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 6.2 billion |
|
Revenue Forecast in 2030 |
US$ 25.47 billion |
|
CAGR |
17% |
|
Base Year for Estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Disease type, Application, End user and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global RNAi therapeutics market was valued at US$ 6.2 billion in 2021 and is expected to register a revenue CAGR of 17% to reach US$ 25.47 billion by 2030.
RNAi Therapeutics Market Fundamentals
RNA interference (RNAi) is a widely researched biological response to double-stranded RNA that controls resistance to both endogenous parasite and external pathogenic nucleic acids and regulates protein-coding gene expression. This natural method for sequence-specific gene silencing has the potential to transform experimental biology and may have significant practical implications in functional genomics, therapeutic intervention, agriculture, and other fields. RNAi is often triggered by foreign DNA and double-stranded RNA (dsRNA), which is a feature of parasitic and harmful (viral) RNA. RNAi is a biological system that is found in all eukaryotic cells, including plants. Several enzymes and proteins in a cell are involved in RNA processing and can direct the RNAi pathway. Dicer and Drosha (both RNAse II enzymes) first convert the trigger RNA into a short interfering RNA (siRNA). The siRNAs are then put into an RNA-induced silencing complex (RISC).
[289340]
RNAi Therapeutics Market Dynamics
Increasing usage of RNAi therapeutics for the treatment of neurodegenerative disorders is expected to create new business opportunities in the market. For instance, Silence Therapeutics' mRNAi GOLD technology is intended to deliver gene-silencing therapy to particular liver cells in the body by mixing siRNA molecules with chemical address tags termed GaINAc, a naturally occurring sugar that attaches exclusively to liver cells. These RNAi molecules can then enter liver cells and silence disease-associated genes that are expressed there.
Rise in the partnership activities between drug distribution firms and contract research organizations (CROs) is projected to help in driving the expansion of the RNAi therapeutics industry. On June 21, 2021, Arrowhead Pharmaceuticals Inc and Horizon Therapeutics plc announced a global collaboration and license agreement for ARO-XDH, a previously unknown discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for individuals with uncontrolled gout. Arrowhead Pharmaceuticals' collaboration with Horizon also represents an expansion of the company's rapidly growing pipeline of investigational RNAi therapeutics based on the company's proprietary Targeted RNAi Molecule (TRiMTM) platform.
However, high cost of developing RNAi therapeutics is expected to hamper the market revenue growth to some extent.
RNAi Therapeutics Market Ecosystem
The global RNAi therapeutics market is analyzed from four perspectives: disease type, application, end-user, and region.
RNAi Therapeutics Market by Disease Type
[298409]
Based on the disease type, the global RNAi therapeutics market is segmented into RNA interference (RNAi) and RNA antisense.
The RNA antisense segment is expected to register the fastest-revenue growth during the forecast period. The benefit of RNA antisense treatment is that it can be produced quickly, has a long therapeutic impact, and is very specific to the target. Antisense drugs are also effective in other therapeutic uses, such as cancer treatment.
RNAi Therapeutics Market by Application
Based on the application, the global RNAi therapeutics market is segmented into oncology, ocular disorders, respiratory disorders, hepatitis B and C, autoimmune hepatitis, neurological disorders, and others.
The oncology segment dominates the market. Rising prevalence of cancer in the global population is boosting the demand for effectual treatment solutions. According to the International Agency for Research on Cancer's GLOBOCAN 2020 study, estimated 19,292,789 new instances of cancer were identified in 2020, with an estimated 9,958,133 individuals dying due to cancer worldwide. According to the same source, of the total diagnosed cancer cases, 10,065,305 were reported in males and 9,227,484 in females. Male cancer cases were anticipated to reach 15,585,096 by 2040, while female cancer cases were expected to reach 13,302,846 by 2040. Hence, increasing prevalence of cancer among the global population is likely to fuel revenue growth in the oncology segment during the forecast period.
RNAi Therapeutics Market by End-user
Based on the end-user, the global RNAi therapeutics market is segmented into research institutes and hospitals & clinics.
The research institutes segment is expected to register the fastest revenue growth during the forecast period. This can be ascribed to rise in the collaboration among research organizations, academic research institutions, or government agencies to bear the high cost of research activities.
RNAi Therapeutics Market by Region
Based on the region, the global RNAi therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the world (RoW).
North America is projected to attract profitable prospects during the forecast period due to increase in cases of target diseases and expanding demand for sophisticated therapies and diagnostics in the region. According to the American Cancer Society, about 1.9 million new cancer cases are likely to be diagnosed in the U.S. in 2022. Furthermore, around 80% of patients diagnosed with cancer in the U.S. are in the age group of 55 or older, with 57% being 65 or older. As a result of the high prevalence of cancer and rise in the elderly population, the need for diagnostics and treatment solutions is significant in the country. This factor is expected to fuel the market revenue growth in the U.S.
Moreover, the market in Europe is expected to register the fastest-revenue growth due to rise in the demand for mRNA vaccinations and therapies to build transformational pharmaceuticals. For instance, Moderna is expanding its business throughout Europe and the U.S. biotechnology development to allow the distribution of mRNA inoculations and therapies locally. This strategy is likely to increase the demand for mRNA inoculations and accelerate the market revenue growth during the forecast period.
RNAi Therapeutics Market Competitive Landscape
The prominent players operating in the global RNAi therapeutics market are:
RNAi Therapeutics Market Strategic Developments
Europe is the key revenue growth region for the global RNAi therapeutics market.
Rising applications of RNAi therapeutics in molecular diagnostics, specifically in cancer, and advancements in synthetic delivery carriers and chemical modifications to RNA are the major factors driving the revenue growth in the global RNAi therapeutics market.
The global RNAi therapeutics market is expected to be valued at US$ 25.47 billion by 2030.
The global RNAi therapeutics market is expected to register a revenue CAGR of 17% during the forecast period.
*Insights on financial performance is subject to availability of information in public domain